We are hiring: ASSISTANT RESEARCH SCIENTIST AT THE PSA CARE HUB AT YORK UNIVERSITY

We are hiring: ASSOCIATE RESEARCH SCIENTIST AT THE PSA CARE HUB AT YORK UNIVERSITY

#PsACAREHub #PsoriaticArthritis #AutoimmuneResearch #Immunology #AcademicHiring #ScienceJobs #Rheumatology

📢 Help us spread the word! Like, share, and tag potential candidates who may be interested in joining the PsA CARE Hub. Together, we can drive innovation and improve outcomes for people living with PsA.

🔍 We're Hiring! We will soon be recruiting Associate and Assistant Research Scientists to join this groundbreaking initiative. If you're a scientist passionate about inflammation, immunology, or any field that can be applied to PsA research, stay tuned for opportunities!

focused on unraveling the cellular and molecular mechanisms driving PsA. By providing mentorship, cutting-edge resources, and a collaborative research environment, the Hub will empower the next generation of researchers to establish independent programs dedicated to PsA discovery.

PsA remains an underexplored disease at the mechanistic level, limiting the development of innovative treatments. The PsA CARE Hub, based at @YorkUniversity and funded by the @KrembilF, will address this critical gap by recruiting and supporting early-career scientists

🚨 Exciting Announcement!

We are thrilled to launch the Psoriatic Arthritis Collaborative and Applied Research Excellence (PsA CARE) Hub, the first research initiative in Canada dedicated to advancing the basic science of psoriatic arthritis (PsA).

Curious about the details? Check out the full paper here: www.sciencedirect.com/science/arti...
Big shoutout to our amazing team and BIG thanks to the funding agencies that supported this work! CIHR, Arthritis Society of Canada and Banting Research Foundation

Next steps? Targeting TRAF1/cIAP2 interaction with small molecules or biologics! Could this be the next generation of RA therapy? Let’s find out.

Unlike current RA therapies that block cytokines, our approach prevents inflammation at its source—without broad immune suppression. This could help patients who don’t respond to existing treatments!

✅ Protected against LPS-induced septic shock
✅ Significantly reduced joint inflammation & disease severity in an RA model

This suggests that disrupting TRAF1/cIAP2 signaling lowers inflammation without shutting down immunity!

🟩 The V203A mutation blocks TRAF1’s interaction with cIAP2.
🟩This shuts down TRAF1’s ability to amplify TLR4-driven inflammation.
🟩As a result, inflammatory cytokine production is significantly reduced.

We asked: Can we selectively disrupt TRAF1’s inflammatory function while keeping its protective role intact? Using CRISPR gene editing, we identified a mutation (V203A in humans, V196A in mice) that does just that!

TRAF1 is an immune signaling adapter linked to RA risk. It has a paradoxical role: it can both promote and suppress NF-κB & MAPK signaling. This complexity has made it hard to target therapeutically.

#RA is an autoimmune disease where chronic inflammation leads to joint damage. Current treatments target inflammatory cytokines, but many patients don’t respond or develop resistance. We need new approaches!

Selective disruption of Traf1/cIAP2 interaction attenuates inflammatory responses and rheumatoid arthritis Tumor necrosis factor receptor-associated factor 1 (TRAF1) is an immune signaling adapter protein linked to increased susceptibility to rheumatoid art…

Excited to share our latest study on #RheumatoidArthritis (RA) in Journal of Autoimmunity! We identified a critical mutation in TRAF1 that selectively reduces inflammation—offering a promising new therapeutic strategy. www.sciencedirect.com/science/arti...

Please share with your network. We are migrating Canadian Women in STEM to Bluesky from the other site.

Our new website is up and running.

Please Join and follow @cdnwomenstem.bsky.social

Happy holidays from the Abdul-Sater lab ♥️♥️

"reviewer 1" had a page and a half of comments 🙂

I don't know why "Reviewer 2" gets a bad rap. We got the reviews back on a new submission and here's Rev 2's comments:
"Reviewer #2: The results are persuasive, and the argument is straightforward. I did not find any major problems."

Deal!

Would be nice if made available on zoom 🙂

Welcome to bsky @chrisperrymito.bsky.social 💪

Congrats, Sunny! Great work

Image of a Globe & Mail op-ed on measles. For an accessible read see http://www.bowdish.ca/lab/2024/03/07/measles-is-not-a-harmless-childhood-infection-dr-bowdish-explains/

I spoke to the CBC Radio about a large measles outbreak in New Brunswick - article link below. I cannot stress enough how serious an infection measles is - recycling an op-ed I wrote on the topic(see link on my webpage for explainer video).

www.cbc.ca/news/canada/...

www.bowdish.ca/lab/2024/03/...

Here are my first impressions after using this platform for a few days: Bluesky is like Twitter if it went on a detox—no hate, no fake news, just good vibes and civilized conversations 😀